Two Pharma Giants, Two High-Stakes Bets: GSK Expands Cancer Pipeline as Novartis Absorbs $1.9 Billion Trial Setback
GSK and Novartis illustrate the high-risk, high-reward nature of pharmaceutical innovation. GSK is accelerating its oncology strategy, expanding clinical trials and investing billions in promising cancer therapies. Meanwhile, Novartis has taken a $1.9 billion impairment charge following a major drug-trial setback, even as strong sales from newer medicines support its outlook. Together, their experiences reveal how clinical breakthroughs, costly failures, patent pressures and aggressive R&D investment are reshaping the future of Big Pharma.
.webp){kind=spacer}
-v3.jpg)
